Inhibrx Biosciences, Inc.

PDUFA AI-extracted

ozekibart

unresectable or metastatic conventional chondrosarcoma

Resolved

102days ago

FDA decision · Mar 27, 2026

What's at stake The FDA's approval decision on ozekibart for unresectable or metastatic conventional chondrosarcoma is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.

Primary source · SEC 8-K verified 13h ago

“the FDA has set a PDUFA action date of March 27, 2026”

Add to calendar Post on X Reddit

Provenance